FDA grants final approval for pioglitazone tablets

02/17/2013 | Pharmaceutical Business Review Online

Aurobindo Pharma received final FDA approval to market its pioglitazone tablets in 15 mg, 30 mg and 45 mg strengths and pioglitazone hydrochloride plus metformin hydrochloride tablets in 15 mg (base)/500 mg and 15 mg (base)/850 mg doses to treat type 2 diabetes.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Teaching Associate (Hospitality Management)
University of Illinois at Urbana-Champaign
Urbana, IL
Director, Global Regulatory Affairs
Rodan and Fields, LLC
San Francisco, CA